Your browser doesn't support javascript.
loading
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood, Matthew L; Liu, Yao; Harkins, Shannon K; Weinstock, David M; Yang, Lei; Stevenson, Kristen E; Plana, Olivia D; Dong, Jingyun; Cirka, Haley; Jones, Kristen L; Virtanen, Anniina T; Gupta, Dikshat G; Ceas, Amanda; Lawney, Brian; Yoda, Akinori; Leahy, Catharine; Hao, Mingfeng; He, Zhixiang; Choi, Hwan Geun; Wang, Yaning; Silvennoinen, Olli; Hubbard, Stevan R; Zhang, Tinghu; Gray, Nathanael S; Li, Loretta S.
Affiliation
  • Arwood ML; Molecular and Translational Cancer Biology Program, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
  • Liu Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Harkins SK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Cancer Biology Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Biological and Biomedical Sciences Program, Harvard Medical School, Boston, MA 02115, USA.
  • Yang L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Stevenson KE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Plana OD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Dong J; Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY 10016, USA; Skirball Institute of Biomolecular Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
  • Cirka H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Jones KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Virtanen AT; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Gupta DG; Molecular and Translational Cancer Biology Program, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
  • Ceas A; Molecular and Translational Cancer Biology Program, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA.
  • Lawney B; Center for Cancer Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Yoda A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Leahy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Hao M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • He Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Choi HG; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Wang Y; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Silvennoinen O; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • Hubbard SR; Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY 10016, USA; Skirball Institute of Biomolecular Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
  • Zhang T; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Gray NS; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: nsgray01@stanford.edu.
  • Li LS; Molecular and Translational Cancer Biology Program, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA; Department of Pediatrics, Division of Hematology, Oncology, and Stem Cell Transplantation, Northwestern University Feinbe
Cell Chem Biol ; 30(6): 618-631.e12, 2023 06 15.
Article in En | MEDLINE | ID: mdl-37290440
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myeloproliferative Disorders Limits: Humans Language: En Journal: Cell Chem Biol Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myeloproliferative Disorders Limits: Humans Language: En Journal: Cell Chem Biol Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos